Nevertheless, although the initial significant benefit, the efficacy of crizotinib, similarly to what happens with EGFR TKI in EGFR-mutant NSCLC, decreases after the onset of acquired resistance mechanisms, mainly secondary mutations in the ALK gene and activation of bypass tracks. This evidence concerns the gene ALK and non-small cell lung carcinoma.